Key Points
- Liquidia director Stephen Bloch sold 235,477 shares at an average price of $27.13, generating approximately $6.39 million in proceeds. The insider transaction was disclosed in an SEC filing.
- Liquidia reported quarterly revenue of $171.68 million, up 1,842.1% year over year, but adjusted earnings of $0.74 per share fell short of the $0.76 consensus estimate.
- Analyst sentiment is mixed: the stock has an average rating of Hold and a consensus price target of $83.69, while recent firms have lowered ratings or targets despite some continued Buy recommendations.
Liquidia Corporation (NASDAQ:LQDA - Get Free Report) Director Stephen Bloch sold 235,477 shares of the firm's stock in a transaction on Monday, October 5th. The stock was sold at an average price of $27.13, for a total value of $6,388,491.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Liquidia Stock Up 3.0%
Shares of LQDA stock opened at $26.68 on Thursday. Liquidia Corporation has a 1-year low of $21.94 and a 1-year high of $93.61. The stock's fifty day moving average price is $68.07 and its 200 day moving average price is $61.99. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. The company has a market cap of $2.39 billion, a price-to-earnings ratio of 19.47 and a beta of 0.61.
Liquidia (NASDAQ:LQDA - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. During the same period in the prior year, the company earned ($0.49) earnings per share. The company's quarterly revenue was up 1842.1% on a year-over-year basis. On average, research analysts expect that Liquidia Corporation will post 2.1 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of research firms recently commented on LQDA. Raymond James Financial cut shares of Liquidia from a "strong-buy" rating to an "outperform" rating and lowered their target price for the stock from $106.00 to $53.00 in a research note on Thursday, October 1st. Wall Street Zen lowered shares of Liquidia from a "buy" rating to a "hold" rating in a research note on Saturday, October 3rd. Wedbush set a $58.00 price target on shares of Liquidia in a report on Friday, October 2nd. Piper Sandler set a $129.00 price target on shares of Liquidia in a report on Friday, July 24th. Finally, Zacks Research downgraded shares of Liquidia from a "hold" rating to a "strong sell" rating in a research note on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $83.69.
Read Our Latest Report on Liquidia
Institutional Trading of Liquidia
Large investors have recently made changes to their positions in the business. WINTON GROUP Ltd acquired a new stake in shares of Liquidia in the second quarter worth $335,000. Arizona State Retirement System boosted its holdings in Liquidia by 5.4% in the second quarter. Arizona State Retirement System now owns 17,627 shares of the company's stock valued at $1,405,000 after purchasing an additional 900 shares during the last quarter. Nykredit A S purchased a new stake in Liquidia in the second quarter valued at $177,000. Corient Private Wealth LP acquired a new stake in Liquidia during the 2nd quarter worth about $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Liquidia during the 2nd quarter worth about $1,236,000. 64.54% of the stock is owned by hedge funds and other institutional investors.
Liquidia News Roundup
Here are the key news stories impacting Liquidia this week:
- Positive Sentiment: HC Wainwright maintained a Buy rating and a $58 price target, well above recent trading levels. The firm continues to project long-term profitability, including estimated EPS of $2.72 in fiscal 2026 and $6.14 in fiscal 2030. HC Wainwright estimates
- Positive Sentiment: An analysis argued that Liquidia could be approximately 74% undervalued, suggesting substantial upside if the company resolves uncertainty surrounding access to YUTREPIA and successfully commercializes the product. Liquidia valuation analysis
- Neutral Sentiment: HC Wainwright reduced its EPS forecasts across 2026–2030, including cuts to fiscal 2026 EPS from $3.44 to $2.72 and fiscal 2030 EPS from $10.08 to $6.14. However, the analyst retained the Buy rating and $58 target, indicating lower estimates but continued confidence in the longer-term story. HC Wainwright estimate revisions
- Negative Sentiment: Director Stephen Bloch sold 235,477 shares worth approximately $6.39 million at an average price of $27.13. A sizable insider sale can pressure sentiment because it may be interpreted as reduced confidence or simply portfolio diversification. SEC insider sale filing
- Negative Sentiment: Two law firms announced shareholder investigations into potential securities claims involving Liquidia. These announcements are often solicitation-driven, but they add litigation overhang and could increase uncertainty for investors. Liquidia investigation alert Shareholder investigation notice
Liquidia Company Profile
(
Get Free Report)
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.
Liquidia's lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
